What to do with Avandia sales force?

You can't take a hit on your biggest drug without bleeding, and GlaxoSmithKline is no exception. In the two weeks since the FDA told Glaxo to slap a heart-attack warning label on Avandia, prescriptions slid by 40 percent, and now the drug maker appears set to slash its Avandia sales force.

Glaxo is preparing a new marketing strategy for the drug, and options include laying off sales staff and/or reassigning reps to other drugs. According to the Telegraph, cuts may go as deep as 500 in the U.S., where the company maintains an overall sales force of 9,000. 

- see this FierceBiotech report
- read the report from The Telegraph

Related Articles:
Expert committee says Avandia should stay. Report
FDA expert wants Avandia withdrawn. Report
Docs shunning Avandia in wake of safety study. Report
Avandia risks exposed under deal to post data. Report
Avandia controversy sparks FDA criticism. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.